What is the role for antithrombotics in cancer care? Interactive session with panel discussion

Cancer Treatment Reviews

Volumn 28, Issue 3, 2002, Pages 157-159

  Kakkar, Ajay K ^a,f   Levine, Mark N ^b   Prandoni, Paolo ^c   Lee, Agnes Y ^b   Rasmussen, Morten S ^d   Kuter, David ^e  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF PADOVA   (Italy)

^d BISPEBJERG HOSPITAL   (Denmark)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

BLOOD FILTER; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CASE REPORT; DEEP VEIN THROMBOSIS; DISEASE ACTIVITY; GASTROINTESTINAL HEMORRHAGE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INFERIOR CAVA VEIN; LUNG EMBOLISM; MALE; MALIGNANT NEOPLASTIC DISEASE; NOTE; PATIENT CARE; PROPHYLAXIS; RECTUM CARCINOMA; RECTUM SURGERY; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0036623177     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-7372(02)00045-2     Document Type: Note

References (2)

1. Bergqvist D, Agnelli G, Cohen A, Eldor A, Nilsson P. Prolonged vs in-hospital thromboprophylaxis with enoxaparin after surgery for abdominal malignancy: results of Enoxacan II. Thromb Haemost 2001: OC1731.
2. Rasmussen M, Jorgensen L, Wille-Jorgensen P, Nielsen J, Soemod L, Harvald T, et al. Prolonged prophylaxis with dalteparin after major abdominal surgery. Thromb Haemost 2001: OC1733.